Long-Term Effects of Caffeine Therapy for Apnea of Prematurity
Top Cited Papers
- 8 November 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (19) , 1893-1902
- https://doi.org/10.1056/nejmoa073679
Abstract
Methylxanthine therapy is commonly used for apnea of prematurity but in the absence of adequate data on its efficacy and safety. It is uncertain whether methylxanthines have long-term effects on neurodevelopment and growth.Keywords
This publication has 23 references indexed in Scilit:
- Reported Medication Use in the Neonatal Intensive Care Unit: Data From a Large National Data SetPediatrics, 2006
- Caffeine Therapy for Apnea of PrematurityNew England Journal of Medicine, 2006
- Caffeine for Apnea of PrematurityNew England Journal of Medicine, 2006
- Minimising ventilator induced lung injury in preterm infantsArchives of Disease in Childhood: Fetal & Neonatal, 2005
- Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) TrialNeonatology, 2005
- Preterm outcomes research: A critical component of neonatal intensive careMental Retardation and Developmental Disabilities Research Reviews, 2002
- Severity of Neonatal Retinopathy of Prematurity Is Predictive of Neurodevelopmental Functional Outcome at Age 5.5 YearsPediatrics, 2000
- Methylxanthine therapy in premature infants: Sound practice, disaster, or fruitless byway?The Journal of Pediatrics, 1999
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988
- Efficacy of caffeine in treatment of apnea in the low-birth-weight infantThe Journal of Pediatrics, 1977